Please login to the form below

Not currently logged in


This page shows the latest CMA news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

to gain access to the treatment following its CMA by MHRA through Project Orbis. ... The CMA for Lumykras is based on clinical evidence from the phase 2 CodeBreaK 100 trial which evaluated the drug in 126 patients with KRAS G12C- mutated advanced NSCLC.

Latest news

More from news
Approximately 8 fully matching, plus 19 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
Box 1
Strategic commitment
KOL Ambassador Program & Podcast Creation: A Customer Story